MARKET

THAR

THAR

Tharimmune Inc
NASDAQ
1.450
0.000
0.00%
After Hours: 1.440 -0.01 -0.69% 18:03 03/14 EDT
OPEN
1.450
PREV CLOSE
1.450
HIGH
1.470
LOW
1.450
VOLUME
9.97K
TURNOVER
--
52 WEEK HIGH
7.46
52 WEEK LOW
1.280
MARKET CAP
2.80M
P/E (TTM)
-0.0786
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at THAR last week (0303-0307)?
Weekly Report · 4d ago
Tharimmune announces expansion of product pipeline with HS1940
TipRanks · 03/04 12:26
Tharimmune Expanded Its Product Pipeline With HS1940, A Dual-target Multispecific Biologic Engineered To Bind To Both Programmed Death-1 And Vascular Endothelial Growth Factor Receptors
Benzinga · 03/04 12:07
Weekly Report: what happened at THAR last week (0224-0228)?
Weekly Report · 03/03 11:01
THARIMMUNE INC - APPOINTS DON KIM AS CFO EFFECTIVE MARCH 27, 2025
Reuters · 02/27 21:50
Weekly Report: what happened at THAR last week (0217-0221)?
Weekly Report · 02/24 11:01
Weekly Report: what happened at THAR last week (0210-0214)?
Weekly Report · 02/17 10:59
Weekly Report: what happened at THAR last week (0203-0207)?
Weekly Report · 02/10 10:54
More
About THAR
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.

Webull offers Tharimmune Inc stock information, including NASDAQ: THAR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, THAR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading THAR stock methods without spending real money on the virtual paper trading platform.